Neupharma
Neupharma is a young and modern company focused on innovation in the field of rare diseases, particularly cystic fibrosis. Its mission is to offer patients tools to improve their health and quality of life, including medications, specific foods, and medical devices. The company invests heavily in research, development, and innovation, and has established important partnerships with international companies. Neupharma owns patents developed independently and in collaboration with prestigious Italian universities. It is based in Imola, Italy, and has been recognized for its contributions to healthcare and social initiatives.
Industries
Nr. of Employees
small (1-50)
Neupharma
Patents
Products
Aerosolized/inhaled antibiotic therapies
Line of inhalation antibiotic formulations developed for pulmonary delivery to treat bacterial lung infections in patients with chronic respiratory conditions.
Foods for special medical purposes and supplements
Medical foods and nutritional supplements formulated for conditions with malabsorption or increased nutritional needs (examples: osteogenesis imperfecta, Ehlers-Danlos, deficiency rickets and cystic fibrosis-related needs).
Respiratory support medical devices (nasal lavage and related devices)
Medical devices for nasal washing and other respiratory supportive care marketed and distributed for patient use.
Aerosolized/inhaled antibiotic therapies
Line of inhalation antibiotic formulations developed for pulmonary delivery to treat bacterial lung infections in patients with chronic respiratory conditions.
Foods for special medical purposes and supplements
Medical foods and nutritional supplements formulated for conditions with malabsorption or increased nutritional needs (examples: osteogenesis imperfecta, Ehlers-Danlos, deficiency rickets and cystic fibrosis-related needs).
Respiratory support medical devices (nasal lavage and related devices)
Medical devices for nasal washing and other respiratory supportive care marketed and distributed for patient use.
Services
Maintenance, technical support and servicing for aerosol/nebulizer devices used in respiratory therapy; service offering linked to specific device families.
Online reserved area for medical and healthcare personnel to access technical information and resources.
Maintenance, technical support and servicing for aerosol/nebulizer devices used in respiratory therapy; service offering linked to specific device families.
Online reserved area for medical and healthcare personnel to access technical information and resources.
Expertise Areas
- Cystic fibrosis therapeutics and care
- Inhalation drug delivery development
- Clinical trial management (early-phase)
- Orphan drug regulatory strategy
Key Technologies
- Aerosolized/inhalation drug delivery
- Inhalation formulation development
- Sublingual/mucosal delivery strategies
- Foods for Special Medical Purposes (FMSP) formulation
News & Updates
Neupharma supports the non-profit organization “Imagine To Help” and introduces the “Project Eyes” to aid the Masai community in Kenya.
Neupharma supports Mr. Pietro Armani's association for cystic fibrosis patients from Belarus, Ukraine, and Kazakhstan.
A vehicle was donated for home assistance and social transport for sick people.
Neupharma celebrates its 10th corporate anniversary.
Teicoplanin in inhalation formula received orphan drug designation for cystic fibrosis, developed by Neupharma in collaboration with Rare Partners.
Neupharma acquired 15% of the research company PlumeStars, which specializes in inhalation formulations for rare diseases.
Neupharma supports the non-profit organization “Imagine To Help” and introduces the “Project Eyes” to aid the Masai community in Kenya.
Neupharma supports Mr. Pietro Armani's association for cystic fibrosis patients from Belarus, Ukraine, and Kazakhstan.
A vehicle was donated for home assistance and social transport for sick people.
Neupharma celebrates its 10th corporate anniversary.
Teicoplanin in inhalation formula received orphan drug designation for cystic fibrosis, developed by Neupharma in collaboration with Rare Partners.
Neupharma acquired 15% of the research company PlumeStars, which specializes in inhalation formulations for rare diseases.